Advocacy

In a 2010 commentary in The American Journal of Human Genetics, an ASHG task force analyzed key scientific and non-scientific aspects of genetic ancestry inference in academia and industry, and provided recommendations to advance discussion and facilitate the development of guidelines concerning the use of these technologies. The commentary built upon a previous statement by... Read More

After GINA’s passage in May 2008, ASHG responded to a Federal Register Request for Information on issues related to the law’s implementation. ASHG provided comment on definitions that would ensure the regulations keep pace with scientific and clinical advances, and clarified that data collected prior to GINA’s passage should still be covered by the law.... Read More

In 2007, geneticist James Watson was quoted regarding alleged intellectual inferiority among Africans. ASHG found the comments to be tragically misguided and without scientific foundation. Related: Statement: ASHG response to Recent Comments on Intellectual Ability (November 2007) Read More

With the rise of direct-to-consumer (DTC) genetic tests – tests that are ordered directly by consumers and whose results are reported without a health provider’s involvement – ASHG issued a statement in 2007 on such tests that make health-related claims or directly affect health care decision making. The statement includes recommendations to ensure transparency, provider... Read More

In 2016, ASHG responded to the NIH’s proposed policy for the sharing of data obtained from NIH-supported or -conducted genome-wide association studies (GWAS). ASHG supports broad access to phenotypic and genotypic data to advance medical research, and supported the proposed policy with changes. Related: Comments to NIH on Genome-Wide Association Studies (November 2006) Read More